BioSpace News Archive

HPOne and FDS Announce Strategic Partnership to Expand Medicare Education and Enrollment Services to Pharmacies and their Patients

Lumen Bioscience , a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional

Promega today launched its benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, developed in collaboration with Hitachi High-Tech. The personal CE system is an integrated DNA analysis instrument that enables life scientists in laboratories of all sizes to perform Sanger sequencing and fragment

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman , Nevro’s Chairman, CEO and President, will present at the following conferences: Wells Fargo 2020 Virtual Healthcare Conference

Cybin Corp. (the “Company or “Cybin”), a life sciences company advancing psychedelic pharmaceuticals, is pleased to announce that Mr. Doug Drysdale has been appointed as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005388/en/ Mr. Doug Drysdale, CEO of Cybin Corp. (Photo: Business Wire) Doug has more than 30 years of experienc

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference. For the Morgan Stanley Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Tuesday, Septemb

Renowned Hospital in Turin, Italy Uses Innovative Radiation Therapy Delivery System to Expand Options for Advanced Cancer Care to More Patients

eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage crisis, today announced the appointment of Michael Curtis, Ph.D., as President of Research & Development (R&D

Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations, as well as the status of the filing of Emmaus’ Annual Report on Form 10-K for the year ended December 31, 2019

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN®